Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
Completed
Conditions studied: Cancer
In brief
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer. PURPOSE: This laboratory study is looking at an assay in determining cancer resistance in patients with metastatic cancer and in healthy participants.
Key facts
- Study ID
- NCT00899496
- Run by
- Wake Forest University Health Sciences
- People needed
- 54
- Starts
- 2005-09-01
- Expected to finish
- 2009-10-23
- Last updated by the study team
- 2017-05-30
Who can join
Age: any, up to 120. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Meets 1 of the following criteria:
- Diagnosis of metastatic cancer including, but not limited to, any of the following:
- Stage IV non-small cell lung cancer
- Extensive-stage small cell lung cancer
- Metastatic testicular cancer
- Stage IV breast carcinoma
- Stage III or IV ovarian carcinoma
- Stage IV endometrial carcinoma
- Stage IV prostate carcinoma
- Stage IV colorectal or pancreatic cancer
- Stage IV renal cancer
- Stage III or IV non-Hodgkin's lymphoma
- Stage IV bladder cancer
- Stage III multiple myeloma (Salmon-Durie staging)
- Metastatic melanoma
- Metastatic sarcoma
- Healthy participant, meeting the following criteria:
- No prior cancer
- Over 50 years of age
You may not qualify if…
- Serious medical or psychiatric condition that would preclude study compliance
- Chemotherapy or radiotherapy within the past 3 months (patient)
- Prior immunosuppressive therapy or radiotherapy for any disease (healthy participant)
Where it is running
- Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.